Receive The Newest Study Notifications

First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose control during the study period that used the...

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe, ILUVIEN is expected to launch in certain EU countries during the second half of 2019 Alimera Sciences,...

Stone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development in China of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Image: CStone...

Data analysis and clinical trial software specialist, Exploristics, has announced plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0, by the end of the summer. The software offers second-generation...

A new phase of the IGNITE Network will conduct clinical trials of genomic medicine interventions. The National Institutes of Health will fund clinical trials to assess the benefits, applicability and efficacy of applying genomic medicine interventions to improve...

More than 60% of patients have completed their 6-month treatment plan Topline results remain on track for year-end LAVAL, Quebec, June 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V:ACST), a biopharmaceutical innovator...

- This trial, conducted in patients with type 2 diabetes, compared three doses each of Dance 501 inhaled insulin and subcutaneous insulin lispro - June 04, 2019 08:30 AM Eastern Daylight Time Dance Biopharm Holdings, Inc., a privately-held clinical stage biopharma...

Study successfully met its endpoints and provides basis for pivotal Phase 3 trial Syntrix Pharmaceuticals today announced the publication of positive results from two consecutive randomized and double-blind controlled trials that compared desmetramadol to placebo and...

Victory Nutrition International, Inc ("VNI") announces Prodovite VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis. The clinical study paper is published in Food & Nutrition Research, A...

First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, CA, USA I June 03, 2019 I NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,...

Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019 - Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in...

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin...

GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL -- Study objective to determine the effect of elafibranor, a dual PPAR alpha/delta agonist, on fatty acid saturation -- Phase 2 study to evaluate the effect of a 6-week, once...

CyMedica launches new study to evaluate the effectiveness of e-vive™ for reducing pain and improving function by increasing quadriceps strength in patients with knee osteoarthritis CyMedica Orthopedics®, the leading combined digital health and muscle strengthening...

New York Times bestselling author Kurt Eichenwald will be at Crowne Plaza Houston Near Reliant Medical on Thursday, June 13, at 7 p.m. to discuss his 2018 memoir, “A Mind Unraveled,” in which he details his personal battle with epilepsy. The free event is at the...

 - MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 –- World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief Investigator of the MOMENTUM Phase 3 study -- 180 patient 2:1 randomized, double...

Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma MELBOURNE, Australia, June 04, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...

Results, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated clinically meaningful response in patients with urothelial carcinoma whose treatment previously failed, a population with high unmet medical need...

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment in its second pivotal trial, VICTORY-2, a randomized, double-blind,...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is designed to...